The human gamma-herpesviruses, Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus evade host immunity and establish life-long, latent infections. Latent infections are associated with the development of a variety of malignancies, particularly in immunocompromised AIDS patients. There are currently no effective vaccines for this important class of human viruses. We propose to exploit the in vivo mouse gamma- herpesvirus model to test efficacy of genetically engineered viruses as vaccines. We have shown that a latency-deficient virus fails to establish latency in 100% of recipients, and there is no in vivo reversion to wild type virus, thus fulfilling safety criteria for a genetically engineered oncogenic virus. Importantly, the vaccinated mice are protected from both latent and lytic infection following a subsequent challenge with wild type virus, thus showing protective efficacy. In the current proposal, we will further exploit the natural mouse gamma- herpesvirus infection model to test the parameters and immune correlates of protection of the latency-deficient vaccine. In addition, we will explore the vaccination efficacy of a second genetically engineered virus, which is replication-deficient. Finally, we will evaluate the impact of a further deletion of two immune evasion genes on efficacy and immune correlates of protection. Elucidation of mechanisms of protective immunity induced by """"""""proof of concept"""""""" vaccination strategies in the experimental mouse model will provide fundamental basic insight necessary for the development of vaccines for the oncogenic human gamma-herpesviruses.

Public Health Relevance

The gamma-herpesviruses are not cleared by the host immune system, but establish persistent latent infections. They are widely disseminated in the human population and are associated with the development of several types of cancer, especially in immunocompromised AIDS patients. An important clinical goal is to develop vaccines to prevent infection. Study of the experimental mouse model will enhance our understanding of the immune mechanisms involved in controlling infection and reveal fundamental principles that can be applied to human vaccine development. As there are currently no effective vaccines for the gamma- herpesviruses, these studies are highly significant for human health.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
High Impact Research and Research Infrastructure Programs (RC2)
Project #
5RC2CA148250-02
Application #
7943957
Study Section
Special Emphasis Panel (ZCA1-GRB-I (O9))
Program Officer
Read-Connole, Elizabeth Lee
Project Start
2009-09-30
Project End
2011-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
2
Fiscal Year
2010
Total Cost
$500,000
Indirect Cost
Name
Trudeau Institute, Inc.
Department
Type
DUNS #
020658969
City
Saranac Lake
State
NY
Country
United States
Zip Code
12983
Freeman, Michael L; Burkum, Claire E; Cookenham, Tres et al. (2014) CD4 T cells specific for a latency-associated ?-herpesvirus epitope are polyfunctional and cytotoxic. J Immunol 193:5827-34
Freeman, Michael L; Roberts, Alan D; Burkum, Claire E et al. (2014) Promotion of a subdominant CD8 T cell response during murine gammaherpesvirus 68 infection in the absence of CD4 T cell help. J Virol 88:7862-9
Freeman, Michael L; Burkum, Claire E; Lanzer, Kathleen G et al. (2013) Gammaherpesvirus latency induces antibody-associated thrombocytopenia in mice. J Autoimmun 42:71-9
Freeman, Michael L; Burkum, Claire E; Woodland, David L et al. (2012) Importance of antibody in virus infection and vaccine-mediated protection by a latency-deficient recombinant murine ýý-herpesvirus-68. J Immunol 188:1049-56
Freeman, Michael L; Burkum, Claire E; Jensen, Meghan K et al. (2012) ?-Herpesvirus reactivation differentially stimulates epitope-specific CD8 T cell responses. J Immunol 188:3812-9
Freeman, Michael L; Burkum, Claire E; Yager, Eric J et al. (2011) De novo infection of B cells during murine gammaherpesvirus 68 latency. J Virol 85:10920-5
Leang, Ronika Sitapara; Wu, Ting-Ting; Hwang, Seungmin et al. (2011) The anti-interferon activity of conserved viral dUTPase ORF54 is essential for an effective MHV-68 infection. PLoS Pathog 7:e1002292
Freeman, Michael L; Burkum, Claire E; Lanzer, Kathleen G et al. (2011) Cutting edge: activation of virus-specific CD4 T cells throughout ?-herpesvirus latency. J Immunol 187:6180-4
Freeman, Michael L; Lanzer, Kathleen G; Cookenham, Tres et al. (2010) Two kinetic patterns of epitope-specific CD8 T-cell responses following murine gammaherpesvirus 68 infection. J Virol 84:2881-92
Wu, Ting-Ting; Blackman, Marcia A; Sun, Ren (2010) Prospects of a novel vaccination strategy for human gamma-herpesviruses. Immunol Res 48:122-46